1. Turnbull PCB. Introduction: Anthrax history, disease and ecology. Curr Top Microbiol Immunol 2002; 271: 1-19.

2. Grabenstein JD. Anthrax vaccine: A review. Immunol Allergy Clinics North Am 2003; 23: 713-730.

3. Irmak H, Buzgan T, Karahocagil MK, et al. Cutaneous manifestations of anthrax in Eastern Anatolia: A review of 39 cases. Acta Med Okayama 2003; 57: 235-240.

4. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. New Engl J Med 1999; 341: 815-826.

5. Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect 1994; 113: 479-490.

6. Chensue SW. Exposing a killer: Pathologists angle for anthrax. Am J Pathol 2003; 163: 1699-1702.

7. Moayeri M, Leppla SH. The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 2004; 7: 19-24.

8. Brook I. The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002; 20: 320-325.

9. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 1202-1208.

10. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA 2002; 287: 2236-2252.

11. Cinti SK, Saravolatz L, Nafziger D, Sunstrum J, Blackburn G. Differentiating inhalational anthrax from other influenzalike illnesses in the setting of a national or regional anthrax outbreak. Arch Intern Med 2004; 164 : 674-676.

12. Stephenson J. Rapid anthrax test approved. JAMA 2004; 292: 30.

13. (accessed 1/23/05).

14. Lebowich RJ, McKillip BG, Conboy JR. Cutaneous anthrax: A pathologic study with clinical correlation. Am J Clin Pathol 1943; 13: 505-515.

15. Mallon E, McKee PH. Extraordinary case report: Cutaneous anthrax. Am JDermatopathol 1997; 19: 79-82.

16. (accessed 1/23/05).

17. Kaya A, Tasyaran MA, Erol S, Ozkurt Z, Ozkan B. Anthrax in adults and children: A review of 132 cases in Turkey. Eur J Clin Microbiol Infect Dis 2002; 21: 258-261.

18. Karginov VA, Robinson TM, Riemensehneider J, et al. Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen ofBacillus anthraeis. FEMS Immunol Med Microbiol 2004; 40: 71-74.

19. Bast DJ, Athamna A, Duncan CL, et al. Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J Antimicrob Chemother 2004; 54: 90-94.

20. Kenney RT, Yu J, Guebre-Xabier M, et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 2004; 190: 774-782.

Was this article helpful?

0 0
Smoking Solutions

Smoking Solutions

How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution. Get All The Support And Guidance You Need To Be A Success At Quitting Smoking. This Book Is One Of The Most Valuable Resources In The World When It Comes To How To Maintain The Stop Smoking Pledge From Your New Year’s Resolution.

Get My Free Ebook

Post a comment